Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17725623 | 1.00 | USP2 (0.41) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL17760295 | 1.00 | USP2 (0.41) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL23002541 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL17760332 | 0.79 | LMNA (0.46) | SMN1; SMN2KDM4EMAPTCCR5 | |
| SCHEMBL15449851 | 0.78 | KDM4E (0.42) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL15449852 | 0.78 | KDM4E (0.42) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL15437685 | 0.78 | KDM4E (0.42) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL22799096 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL16438699 | 0.77 | USP2 (0.47) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL21843465 | 0.74 | USP2 (0.49) | USP2SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212618-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| US-9850245-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | USP2 4805/4885SMN1; SMN2 1659/4885KDM4E 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.